 CAMBRIDGE, Mass., Aug. 01, 2022 GLOBE NEWSWIRE -- Foghorn Therapeutics Inc. Nasdaq: FHTX, a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced managements participation in the following investor conferences in August. With an initial focus in oncology, Foghorns Gene Traffic Control Platform and resulting broad pipeline has the potential to transform the lives of people suffering from a wide spectrum of diseases. 